Actemra 80 mg/4 ml (IV Infusion)
4 ml vial: ৳ 9,848.40
Medicine Details
| Category | Details |
|---|---|
| Generic | Tocilizumab |
| Company | Roche bangladesh ltd |
| Also available as |
Title
- Actemra (Tocilizumab)
Categories
- Medicine
- Biologics
- Immunosuppressants
Description
- Interleukin-6 (IL-6) receptor antagonist indicated for treatment of various conditions including Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, COVID-19, Cytokine Release Syndrome, Giant Cell Arteritis, and Systemic Sclerosis-Associated Interstitial Lung Disease.
Color Options
- N/A
Dimensions
- N/A
Functions
- Inhibition of IL-6-mediated signaling
- Reduction of inflammation and immune response
Materials
- Recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody
- Immunoglobulin IgG1K subclass
Technical Specifications
- Dosage varies based on condition and patient weight
- Intravenous and subcutaneous administration
- Storage temperature: 2°C to 8°C
- Caution in coadministration with CYP3A4 substrate drugs
Design Elements
- Recombinant protein
- Monoclonal antibody
Usability Features
- Treatment of adults and pediatric patients
Dosage & Administration
- Intravenous infusion or subcutaneous injection
- Dosage regimen based on weight and clinical response
- Interruption of dosing for dose-related laboratory abnormalities
Interaction
- Exercise caution when coadministering with CYP3A4 substrate drugs
Contraindications
- Known hypersensitivity to Tocilizumab
Side Effects
- Common adverse reactions: upper respiratory tract infections, headache, hypertension, increased ALT, injection site reactions
- COVID-19 specific adverse reactions: constipation, anxiety, diarrhea, insomnia, hypertension, nausea
Pregnancy & Lactation
- May cause fetal harm based on animal data
- Use during pregnancy only if potential benefit justifies potential risk
Precautions & Warnings
- Do not administer during active infection
- Evaluation for tuberculosis risk factors prior to initiation
- Monitor for signs and symptoms of hepatic injury
- Hypersensitivity reactions reported
Use in Special Populations
- Safety and effectiveness not established in certain pediatric and geriatric populations
- No dose adjustment required in mild or moderate renal impairment
Overdose Effects
- Monitor for signs and symptoms of adverse reactions in case of overdose
- Provide appropriate symptomatic treatment for adverse reactions
Therapeutic Class
- Drugs used for Rheumatoid Arthritis
Storage Conditions
- Store at 2°C to 8°C, do not freeze